Akari Therapeutics Plc ROCE
What is the ROCE of Akari Therapeutics Plc?
The ROCE of Akari Therapeutics Plc is -220.95%
What is the definition of ROCE?
Return on capital employed (ROCE) is a financial ratio that measures a company’s profitability and the efficiency with which its capital is used.
= EBIT / (assets - current liabilities)
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
ROCE of companies in the Health Care sector on NASDAQ compared to Akari Therapeutics Plc
What does Akari Therapeutics Plc do?
akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. akari’s lead drug, coversin, a second-generation and potentially best-in-class complement inhibitor, acts on complement component-c5, preventing release of c5a and formation of c5b – 9 (also known as the membrane attack complex or mac). coversin is a recombinant small protein (16,740 da) derived from a native protein discovered in the saliva of the ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response.
Companies with roce similar to Akari Therapeutics Plc
- BioCardia has ROCE of -224.64%
- Sunworks Inc has ROCE of -223.47%
- Soligenix Inc has ROCE of -223.00%
- Katoro Gold plc has ROCE of -222.81%
- DelMar Pharmaceuticals has ROCE of -222.47%
- Applied Therapeutics has ROCE of -222.43%
- Akari Therapeutics Plc has ROCE of -220.95%
- Dore Copper Mining has ROCE of -220.90%
- Applied Genetic Technologies Corp has ROCE of -219.90%
- Intrusion has ROCE of -219.55%
- Galera Therapeutics Inc has ROCE of -218.63%
- Lumos Pharma Inc has ROCE of -217.72%
- AutoWeb Inc has ROCE of -217.47%